Silvia Randone-Bellando

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 175 publications

A distinct gastrointestinal symptom profile characterizes clinically relevant fatigue in systemic sclerosis.

A distinct gastrointestinal symptom profile characterizes clinically relevant fatigue in systemic sclerosis.

Journal: Clinical rheumatology

Published: July 23, 2026

Expert recommendations for the management of fecal incontinence in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Expert recommendations for the management of fecal incontinence in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal: Journal of scleroderma and related disorders

Published: June 19, 2026

Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal: Journal of scleroderma and related disorders

Published: June 18, 2026

The clinical profile of systemic sclerosis without a 'scleroderma pattern' at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology.

The clinical profile of systemic sclerosis without a 'scleroderma pattern' at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology.

Journal: Journal of translational autoimmunity

Published: April 08, 2026

Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains.

Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains.

Journal: Clinical rheumatology

Published: January 19, 2026

Early gastrointestinal manifestations predict disease progression and mortality in patients with systemic sclerosis.

Early gastrointestinal manifestations predict disease progression and mortality in patients with systemic sclerosis.

Journal: Rheumatology (Oxford, England)

Published: January 17, 2026

Scoping literature review on applied definitions of very early diagnosis of systemic sclerosis (VEDOSS) and pre-systemic sclerosis in original articles.

Scoping literature review on applied definitions of very early diagnosis of systemic sclerosis (VEDOSS) and pre-systemic sclerosis in original articles.

Journal: RMD open

Published: January 10, 2026

Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study.

Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study.

Journal: RMD open

Published: January 02, 2026

Early gastrointestinal manifestations predict disease progression and mortality in patients with systemic sclerosis.

Early gastrointestinal manifestations predict disease progression and mortality in patients with systemic sclerosis.

Journal: medRxiv : the preprint server for health sciences

Published: December 18, 2025

Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database.

Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database.

Journal: Rheumatology (Oxford, England)

Published: December 05, 2025

Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database.

Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database.

Journal: Rheumatology (Oxford, England)

Published: December 05, 2025

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort.

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort.

Journal: Arthritis care & research

Published: December 01, 2025

Showing 1-12 of 175

Last Updated: 09/26/2026